Diego A S Toesca1, Faisal Ahmed1, Mehr Kashyap2, J Richelcyn M Baclay1, Rie von Eyben3, Erqi L Pollom1, Albert C Koong4, Daniel T Chang5. 1. Department of Radiation Oncology, Stanford Cancer Institute, Stanford, USA. 2. Stanford University School of Medicine, Stanford, USA. 3. Department of Radiation Oncology, Stanford Cancer Institute, Stanford, USA. Electronic address: rieve@stanford.edu. 4. Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA. 5. Department of Radiation Oncology, Stanford Cancer Institute, Stanford, USA. Electronic address: dtchang@stanford.edu.
Abstract
PURPOSE: We aimed to report the long-term impact of modern chemotherapy and SABR dose regimens on oncologic outcomes of unresectable pancreatic adenocarcinoma (PA). MATERIALS AND METHODS: We reviewed the treatment characteristics and outcomes of all patients who received multi-fraction SABR for unresectable PA between February 2007 and August 2018 at our institution. Time-to-events were calculated from date of diagnosis treating death as a competing risk. RESULTS: A total of 149 patients were identified. Median follow-up was 15 months (range: 5-47). Median SABR dose was 33 Gy (range: 20-45) delivered in 5 fractions in 143 patients, and 3 or 6 fractions in 6 patients. 107 patients (72%) received gemcitabine-based chemotherapy while 31 (21%) received modified FOLFIRINOX (mFFX). Median OS was 16 months (95% CI, 14-17), with a 1-year cumulative incidence of LF of 14%. The combination of SABR doses ≥40 Gy and mFFX (n = 21) showed a superior PFS and OS to the use of GEM-based chemotherapy with <40 Gy SABR doses (median PFS: 14 vs. 10 months, HR: 0.46, 95% CI: 0.29-0.71, P = 0.003; median OS: 24 vs. 14 months, HR: 0.36, 95% CI: 0.22-0.59, P = 0.002), with 1-year PFS and OS of 67% and 90% compared to 35% and 59% for those who received GEM-based chemotherapy with <40 Gy SABR doses, respectively. CONCLUSIONS: The use of mFFX and a SABR dose ≥40 Gy in 5 fractions may be superior compared to regimens that utilize gemcitabine-based chemotherapy or SABR doses <40 Gy.
PURPOSE: We aimed to report the long-term impact of modern chemotherapy and SABR dose regimens on oncologic outcomes of unresectable pancreatic adenocarcinoma (PA). MATERIALS AND METHODS: We reviewed the treatment characteristics and outcomes of all patients who received multi-fraction SABR for unresectable PA between February 2007 and August 2018 at our institution. Time-to-events were calculated from date of diagnosis treating death as a competing risk. RESULTS: A total of 149 patients were identified. Median follow-up was 15 months (range: 5-47). Median SABR dose was 33 Gy (range: 20-45) delivered in 5 fractions in 143 patients, and 3 or 6 fractions in 6 patients. 107 patients (72%) received gemcitabine-based chemotherapy while 31 (21%) received modified FOLFIRINOX (mFFX). Median OS was 16 months (95% CI, 14-17), with a 1-year cumulative incidence of LF of 14%. The combination of SABR doses ≥40 Gy and mFFX (n = 21) showed a superior PFS and OS to the use of GEM-based chemotherapy with <40 Gy SABR doses (median PFS: 14 vs. 10 months, HR: 0.46, 95% CI: 0.29-0.71, P = 0.003; median OS: 24 vs. 14 months, HR: 0.36, 95% CI: 0.22-0.59, P = 0.002), with 1-year PFS and OS of 67% and 90% compared to 35% and 59% for those who received GEM-based chemotherapy with <40 Gy SABR doses, respectively. CONCLUSIONS: The use of mFFX and a SABR dose ≥40 Gy in 5 fractions may be superior compared to regimens that utilize gemcitabine-based chemotherapy or SABR doses <40 Gy.
Authors: Zhan Shi; Ju Yang; Weiwei Kong; Xin Qiu; Changchang Lu; Juan Liu; Baorui Liu; Juan Du Journal: Front Oncol Date: 2022-03-01 Impact factor: 6.244
Authors: Colin S Hill; Lauren M Rosati; Chen Hu; Wei Fu; Shuchi Sehgal; Amy Hacker-Prietz; Christopher L Wolfgang; Matthew J Weiss; Richard A Burkhart; Ralph H Hruban; Ana De Jesus-Acosta; Dung T Le; Lei Zheng; Daniel A Laheru; Jin He; Amol K Narang; Joseph M Herman Journal: Ann Surg Oncol Date: 2022-02-07 Impact factor: 5.344
Authors: Colin Hill; Shuchi Sehgal; Wei Fu; Chen Hu; Abhinav Reddy; Elizabeth Thompson; Amy Hacker-Prietz; Dung Le; Ana De Jesus-Acosta; Valerie Lee; Lei Zheng; Daniel A Laheru; William Burns; Matthew Weiss; Christopher Wolfgang; Jin He; Joseph M Herman; Jeffrey Meyer; Amol Narang Journal: Cancer Med Date: 2022-02-10 Impact factor: 4.452
Authors: Neelam Tyagi; Jiayi Liang; Sarah Burleson; Ergys Subashi; Paola Godoy Scripes; Kathryn R Tringale; Paul B Romesser; Marsha Reyngold; Christopher H Crane Journal: Phys Imaging Radiat Oncol Date: 2021-07-12